PharmaResources (Shanghai) Co., Ltd. (SHE:301230)
China · Delayed Price · Currency is CNY 40.07
+0.47 (1.19%)
At close: Sep 23, 2026
SHE:301230 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 700.02 | 688.35 | 544.47 | 489.72 | 478.88 | 448.21 |
Revenue Growth | 10.86% | 26.43% | 11.18% | 2.26% | 6.84% | 58.38% |
Gross Profit Gross Profit Growth | 173.29 | 176.83 | 130.58 | 139.11 | 174.42 | 170.22 |
Operating Income Operating Income Growth | 14.51 | 22.55 | -8.9 | 26.64 | 60.25 | 86.98 |
Net Income Net Income Growth | 38.26 | 34.29 | 17.08 | 37.62 | 67.18 | 73.58 |
Earnings Per Share EPS Growth | 0.20 | 0.18 | 0.09 | 0.21 | 0.47 | 0.54 |
EPS Growth | 41.57% | 100.00% | -55.56% | -55.57% | -13.59% | 48.83% |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Drug Discovery Drug Discovery Growth | 396.98 | 316.57 | 293.21 | 274.73 | 234.89 |
Process Research and Development Process Research and Development Growth | 63.71 | 48.16 | 77.87 | 80.31 | 92.83 |
Commercial Production Commercial Production Growth | 197.91 | 165.21 | 109.4 | 117.09 | 118.72 |
Unallocated Others Unallocated Others Growth | 29.76 | 14.52 | 9.24 | 6.76 | 1.77 |
Total Total Growth | 688.35 | 544.47 | 489.72 | 478.88 | 448.21 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 286.52 | 312.58 | 340.81 | 550.05 | 780.65 | 113.17 |
Total Debt Total Debt Growth | 144.4 | 165.31 | 181.71 | 206.35 | 100.3 | 108.35 |
Net Cash (Debt) Net Cash Growth | 142.12 | 147.27 | 159.11 | 343.69 | 680.35 | 4.82 |
Net Cash Growth | -12.87% | -7.44% | -53.71% | -49.48% | 14005.50% | -94.56% |
Net Cash Per Share Net Cash Per Share Growth | 0.76 | 0.79 | 0.86 | 1.90 | 4.73 | 0.04 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 168.1 | 135.51 | 80.86 | 20.86 | 99.29 | 105.12 |
Capital Expenditures CapEx Growth | -65.67 | -43.32 | -109.4 | -248.27 | -123.97 | -92.12 |
Free Cash Flow Free Cash Flow Growth | 102.44 | 92.2 | -28.54 | -227.41 | -24.67 | 13.01 |
Free Cash Flow Growth | 167.63% | - | - | - | - | -37.90% |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 24.75% | 25.69% | 23.98% | 28.41% | 36.42% | 37.98% |
Operating Margin | 2.07% | 3.28% | -1.63% | 5.44% | 12.58% | 19.41% |
Pretax Margin | 5.11% | 4.11% | 0.65% | 7.51% | 15.23% | 19.24% |
Profit Margin | 5.47% | 4.98% | 3.14% | 7.68% | 14.03% | 16.42% |
FCF Margin | 14.63% | 13.39% | -5.24% | -46.44% | -5.15% | 2.90% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 |
Dividend Per Share Dividend Per Share Growth | 0.285 | 0.285 | 0.331 | 0.195 | 0.211 |
Dividend Per Share Growth | 0% | -13.97% | 69.47% | -7.66% | - |
Dividend Yield | 0.71% | 1.25% | 1.72% | 0.95% | 0.98% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 23, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 193.66 | 119.80 | 205.47 | 102.42 | 61.13 | - |
Forward PE | 117.00 | 74.67 | 52.62 | 30.60 | - | - |
P/FCF Ratio | 69.28 | 44.56 | - | - | - | - |
PS Ratio | 10.14 | 5.97 | 6.45 | 7.87 | 8.57 | - |